Last reviewed · How we verify
Ivermectin Injectable Product
Ivermectin is a macrocyclic lactone that binds to glutamate-gated chloride channels in parasites and some pathogens, causing paralysis and death.
Ivermectin is a macrocyclic lactone that binds to glutamate-gated chloride channels in parasites and some pathogens, causing paralysis and death. Used for Parasitic infections (onchocerciasis, strongyloidiasis, scabies), Investigational use in COVID-19 and other infectious diseases (phase 3 context suggests expanded indication study).
At a glance
| Generic name | Ivermectin Injectable Product |
|---|---|
| Also known as | Veterinary Ivermectin 1% |
| Sponsor | Barcelona Institute for Global Health |
| Drug class | Antiparasitic agent; macrocyclic lactone |
| Target | Glutamate-gated chloride channels (GluCl) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease; Parasitology |
| Phase | Phase 3 |
Mechanism of action
Ivermectin selectively activates chloride channels in invertebrate nervous and muscular systems, leading to hyperpolarization, paralysis, and death of susceptible organisms. The injectable formulation allows systemic delivery for treatment of parasitic and certain infectious diseases. It has also been investigated for potential antiviral and immunomodulatory properties in various conditions.
Approved indications
- Parasitic infections (onchocerciasis, strongyloidiasis, scabies)
- Investigational use in COVID-19 and other infectious diseases (phase 3 context suggests expanded indication study)
Common side effects
- Mazzotti reaction (fever, pruritus, rash)
- Headache
- Myalgia
- Lymphadenopathy
- Gastrointestinal disturbances
Key clinical trials
- Broad One Health Endectocide-based Malaria Intervention in Africa (BOHEMIA) (PHASE3)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19
- Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients (PHASE1, PHASE2)
- Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |